ReproCELL Incorporated [4978.T]
TOKYO, Jun 11 (Pulse News Wire) – ReproCELL Incorporated (4978.T) announced today that the grant amount for its research project titled “Development of New GPC-1 CAR-T Therapy for Recurrent and Refractory Solid Tumors Positive for GPC-1” has been determined. The grant, part of theAMED-funded initiative aimed at developing foundational technologies for regenerative medicine and gene therapy industrialization, was confirmed at June 11, 2026.
The company received a total of ¥89.7 million as the final approved amount for this project. This funding will be recognized as extraordinary income in the first quarter of the fiscal year ending March 2027.
However, the company stated that this grant will not impact its consolidated earnings forecast for the same period. ReproCELL’s representative director, Shigeishi Yokoyama, highlighted the significance of this grant in advancing their research efforts towards innovative treatments for solid tumors.
The funds will support ongoing development activities and contribute to the broader goals of enhancing regenerative medical therapies.
🟡 Confidence: Standard AI-translated content.